Colorado BioScience Association

1. CBSA
FOCUS
S EP T EMB ER 20 1 0
INSIDE THIS
Letter from the President
ISSUE:
Letter from the 1
President
The CBSA needs your help in ports, bridges and highways, public schools and
Venture Show- 2 defeating three measures ap- colleges.
case Finalists
pearing on this November’s
ballot that are certain to bring Colorado simply cannot provide services to its
Biowest 3-5 long-term harm to the biosci- citizens, attract investment into the state, sup-
Highlights ence industry as a whole and port current bioscience companies here nor
push Colorado’s economy fur- attract new companies to the state if we adopt
ther into recession. Amendments 60 and 61 and Proposition 101.
In effect they will permanently cut back or
Amendments 60 and 61 and Proposition 101 eliminate the taxes and fees that fix our roads,
create an unprecedented $4.2 billion deficit run our schools and staff our prisons and po-
at the state and local level, displacing 73,000 lice.
jobs, terminating over 8,000 classroom
teachers and dramatically increasing fees and The Colorado BioScience Association has
licenses on small business. taken a formal position to oppose these three
job-killing measures. We urge our members
The Rocky Mountain Region's This will happen on top of the 110,000 jobs and their families to inform their friends,
Premier Annual BioScience already lost in Colorado in the last 18 neighbors and colleagues as to the disastrous
Conference and Expo months of the recession. In fact, these meas- effects these measures will have on Colorado’s
ures will trigger a voter-approved, second economic recovery.
September 29-30, 2010 recession.
You can get more information and sign the
These measures eliminate a quarter of the petition at www.DontHurtColorado.com. If
Grand Hyatt income tax, half the public school tax, and all you have any questions, please don’t hesitate
1750 Welton St., Denver of the road and bridge funds generated from to contact CBSA.
car license plates.
www.biowestconference.com Holli Baumunk
These measures simply go too far. They re-
quire payment in advance on the state’s larg-
est infrastructure needs—dams, water and
sanitation projects, power generators, air-
President and CEO
Colorado BioScience Association | www.CoBioScience.com | cbsainfo@CoBioScience.com | 303.592.4073

2. PAGE 2 BioWest 2010 Venture Showcase Finalists
Dorsey & Whitney Venture Showcase Grand Prize
$7,500 prize to be announced at Awards Dinner
This year’s four BioWest Venture Showcase competition PeptiVir, Inc. is an early stage biopharma-
finalists comprise cutting-edge development of a univer- ceutical company focused on the develop-
sal influenza vaccine, creation of an innovative hybrid- ment and commercialization of a conforma-
Cpeptide manufacturing process, groundbreaking waste- tionally-constrained, synthetic peptide-based
water treatment through a new algae production system, vaccine platform for the prevention of viral diseases. Pep-
and a revolutionary nontoxic surface treatment to con- tiVir’s lead product, PVI-1000, has the potential to be a
trol the growth of bacteria in hospitals. “universal” influenza vaccine wherein one or two admini-
strations could lead to sustained protection against multi-
AmideBio is a company in the busi- ple seasonal and pandemic strains. This is in contrast to
ness of improvement of human health existing influenza vaccines that must be generated and
by providing low cost and efficient administered yearly and induce antibodies that provide
manufacturing of peptides for the research and develop- protection only against that year’s seasonal flu strains.
ment markets. The Company’s proprietary hybrid manu- Unlike other universal vaccine strategies that are being
facturing process also enables small scale cGMP manufac- investigated and that focus on inducing cell-mediated im-
turing for clinical trials and the development of generic munity, PVI-1000 is predicted to work by inducing cross-
peptide therapeutics. In order to make progress against reactive antibodies that would protect against multiple
certain diseases and conditions, such as Alzheimer’s, it is influenza virus strains, a prediction that should be readily
necessary to be able to cost-effectively produce large confirmed in humans by examining the biological activity
quantities of peptides for research and development use, of the antibodies produced following vaccination.
and ultimately therapeutic purposes. Current peptide
synthesis technology is unable to produce certain pep- Sharklet Technologies, Inc. is a life
tides at an acceptable cost, or at all. AmideBio’s proprie- sciences company that has engineered a
tary technology enables very cost-effective production of revolutionary surface product called
peptides and thus is a key enabling technology for devel- Sharklet. Sharklet is the first non-toxic,
opment of new therapeutics for diseases for which there long-lasting and no-kill surface used to control the growth
are currently limited or no good treatment options. of bacteria. Sharklet is a patented surface technology
www.amidebio.com comprised of millions of raised, microscopic features ar-
ranged in distinct diamond shapes to form a continuous
BioVantage: In response to pattern. Laboratory tests show that the Sharklet micro-
escalating water scarcity and pattern disrupts several critical microbial colonizing proc-
the undeniable water/energy esses that are necessary for bacteria to develop into a
nexus, BioVantage is developing cost-effective, sustain- disease-causing biofilm. In tests simulating an ambient hos-
able, “green” solutions for wastewater reclamation. pital environment, the Sharklet patterned surface has
Comprised of patent-pending technology and processes, shown to significantly reduce survival and touch transfer
BioVantage’s algae production system produces proprie- of bacteria. Until the advent of Sharklet, kill strategies
tary algae consortia for use in wastewater lagoons to including antibiotics, disinfectants and biocides have been
accelerate natural remediation. This allows a greater de- the primary weapons to control bacterial growth. These
gree of reuse of one of our planet’s most valuable and kill strategies and their overuse has led to increased bac-
scarce resources, water. terial resistance, causing harm to people and the environ-
www.biovantageresources.com ment.
www.sharklet.com

3. Biowest Keynote Speakers PAGE 3
Founder’s Breakfast
Key Steps for Moving Colorado’s Bioscience Industry Forward
Thomas Warwick, Denver District Director, Food and Drug Administration
Tom Warwick began his career as a Chief Science Officer in Denver, CO, in 1977. During his
tenure with the FDA, Tom has served in San Juan, PR; Phoenix, AZ and Minneapolis, MN. After
serving as a CSO and being a supervisor for 13 years, Tom was appointed as the Director of
Compliance Branch in 2004 and then returned to Denver in 2008 as the Denver District Director.
Grand Finale Luncheon
The Year 2020 and the Role of the form, the FDA regulatory approval process,
Venture Capitalist highly skilled immigration, patent reform, U.S.
competitiveness issues, energy reform, support
for basic research funding and countless other
Mark G. Heesen, President,
policy issues that impact America’s entrepre-
National Venture Capital Association
neurial ecosystem.
Mark Heesen has advocated for the venture
capital industry, entrepreneurship and innova- As the primary spokesperson for the venture
tion for nearly two decades, first as NVCA’s capital industry, Mark is often called upon by
head of public policy and, since 1999 as the As- the financial media, NVCA members, limited
sociation’s president. Under Mark’s leadership, partners, and regional associations to offer in-
the NVCA has grown in both scope and scale sights and perspectives on trends and develop-
as it relates to its public policy agenda, research ments occurring within the asset class. He is a
initiatives, and member programs. Mark is con- frequent presenter at industry conferences, a
stantly engaged in legislative and regulatory is- familiar and trusted source in news articles fo-
National Venture
sues surrounding information technology, life cusing on the venture industry, and a recurrent
Capital Association
sciences and clean technology investing, provid- guest on CNBC and Bloomberg Television.
ing strategic direction for the NVCA profes-
Source for venture
sional staff and managing a board of 26 venture
funding information
capital practitioners. Prior to his work at NVCA, Mark was an aide
to a former Governor of Pennsylvania and was
www.nvca.org Deputy Director for Federal Funds reporting to
Mark has taken a leadership position on behalf the Texas Legislature. Mark received a law de-
of the venture capital industry on issues such as gree with an emphasis in taxation from the
carried interest taxation, financial services re- Dickinson School of Law in 1984.

4. PAGE 4
Keynote Luncheon
Health Care in Transition:
The Outlook on What the Industry Should Expect
James Greenwood, President and CEO, BIO
Mark Leahey, President and CEO, MDM
James C. Greenwood is President Commerce Committee, he was
and CEO of the Biotechnology In- widely viewed as a leader on health
dustry Organization (BIO) in Wash- care and the environment.
ington, D.C., which represents more
than 1,200 biotechnology companies,
academic institutions, state biotech- From 2001 to 2004, Mr. Greenwood
nology centers and related organiza- served as Chairman of the Energy
tions across the United States and in and Commerce Committee Subcom-
more than 30 other nations. BIO mittee on Oversight and Investiga-
members are involved in the re- tion with oversight authority over
search and development of innova- issues in the full Committee's vast
tive healthcare, agricultural, industrial jurisdiction. He led hard-hitting in-
and environmental biotechnology vestigations into corporate govern-
products. BIO also produces the ance at Enron, Global Crossing and
annual BIO International Convention, WorldCom; terrorist threats to our
the world's largest gathering of the nation's infrastructure; and waste
biotechnology industry, along with and fraud in federal government
industry-leading investor and part- agencies.
nering meetings held around the
world. Prior to his election to Congress,
Mr. Greenwood served six years in
Since his appointment in January of the Pennsylvania General Assembly
2005, he has markedly enhanced the (1981-86) and six years in the Penn-
trade association’s capacity – increas- sylvania Senate (1987-1992).
ing both its staff and budget by nearly
fifty percent. BIO is now a world Mr. Greenwood graduated from
class advocacy organization playing a Dickinson College in 1973 with a BA
leading role in shaping public policy in Sociology. From 1977 until 1980,
on a variety of fronts critical to the he worked as a caseworker with
success of the biotechnology indus- abused and neglected children at the
try at the state and national levels as Bucks County Children and Youth
well as internationally. Social Service Agency.
Mr. Greenwood represented Penn- Mr. Greenwood is married with
sylvania's Eighth District in the U.S. three children and resides in Upper
House of Representatives from Janu- Makefield, Pennsylvania.
ary 1993 through January 2005. A
senior member of the Energy and

5. PAGE 5
Keynote Luncheon
Continued
Mark Leahey is the Presi- CBSA Areas of Focus
dent & CEO for MDMA, Leadership and Advocacy
a national trade associa-
tion in Washington, DC CBSA promotes the interests of over 400
that represents research- bioscience companies and their 20,000 em-
driven medical technol- ployees and actively communicates the bio-
ogy companies. Mr. Lea- science industry’s issues and challenges on
hey's responsibilities include advocating on multiple fronts.
CBSA Staff behalf of the entrepreneurial sector of the
Holli Baumunk medical device industry to Congress, the Business Solutions
President and CEO FDA, the CMS, and other federal and state
agencies. We provide the resources, community
hbaumunk@cobioscience.com knowledge and a far reaching network to
connect companies and innovators with
April Giles He has lobbied for a more reasonable user local, regional and national partners. Addi-
Executive Vice President fee for smaller companies, worked to open tionally, your CBSA membership helps your
agiles@cobioscience.com access to the hospital marketplace by chal- bottom line by offering access to exclusive
lenging the exclusionary and anti- discounts for companies of all types and
competitive nature of certain large group sizes, from lab equipment to office supplies
Leah Kientz
purchasing organizations (GPOs), as well as and insurance.
Director Public Policy & Pro-
ensure that medical device technologies are
grams
reimbursed adequately. Mr. Leahey cur-
lkientz@cobioscience.com rently sits on the Medical Devices Commit- Economic Development
tee for the Food and Drug Law Institute CBSA plays a key role in promoting Colo-
Mae Desaire (FDLI) and the Editorial Advisory Board of rado as a dynamic region for bioscience
Director of Marketing Medical Product Outsourcing. He is a innovation and investment, by working with
mdesaire@cobioscience.com member of the Massachusetts Bar and a government and community stakeholders
graduate of Georgetown University, the to develop ways to support the creation,
Georgetown Law Center and George- retention and recruitment of life sciences
town’s McDonough School of Business. companies.
216 16th St. Education
Suite 850
CBSA works alongside Colorado’s educa-
Denver, CO 80202
tion institutions to create opportunities
Main number: (303) 592-4073
that promote bioscience workforce devel-
www.cobioscience.com
opment. We create programs that educate
the public, elected officials and business
leaders about the benefits of a vibrant bio-
science community.